Citizens JMP raised the firm’s price target on Argenx (ARGX) to $701 from $696 and keeps an Outperform rating on the shares. Argenx’s Q4 results highlighted another strong quarter for the VYVGART franchise, and as the launch of VYVGART in Chronic Inflammatory Demyelinating Polyneuropathy continues to impress, approval of the pre-filled syringe in April should be a further tailwind, the analyst tells investors in a research note. The firm expects Argenx to deliver robust free cash flow moving forward.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARGX:
- Argenx price target raised to $741 from $723 at Wells Fargo
- Argenx price target raised to $720 from $717 at H.C. Wainwright
- Argenx Se: Promising Outlook with Vyvgart Momentum and Pipeline Expansion Justifies Buy Rating
- Argenx Reports Strong 2024 Financial Results and Strategic Growth
- Argenx Se: Strong Financial Performance and Promising Growth Prospects Drive Buy Rating